E-LIB Suche - Ergebnisse für: Olivença, Francisco

1

Ethambutol and meropenem/clavulanate synergy promotes enhan..:

Olivença, Francisco ; Pires, David ; Silveiro, Cátia...
Antimicrobial Agents and Chemotherapy. 68 (2024) 4 - p. , 2024

2

CRISPRi-mediated characterization of novel anti-tuberculosi..:

Silveiro, Cátia ; Marques, Mariana ; Olivença, Francisco...
Frontiers in Cellular and Infection Microbiology. 13 (2023) - p. , 2023

Link: https://doi.org/10.3389/..

3

Uncovering Beta-Lactam Susceptibility Patterns in Clinical ..:

Olivença, Francisco ; Nunes, Alexandra ; Macedo, Rita...
Microbiology Spectrum. 10 (2022) 4 - p. , 2022

Link: https://doi.org/10.1128/..

4

Identification of drivers of mycobacterial resistance to pe..:

Olivença, Francisco ; Ferreira, Cláudia ; Nunes, Alexandra...
Frontiers in Microbiology. 13 (2022) - p. , 2022

Link: https://doi.org/10.3389/..

5

The Mycobacteriophage Ms6 LysB N-Terminus Displays Peptidog..:

Gigante, Adriano M. ; Olivença, Francisco ; Catalão, Maria João...
Viruses. 13 (2021) 7 - p. 1377 , 2021

Link: https://doi.org/10.3390/..

6

CRISPRi-mediated characterization of novel anti-tuberculosi..:

Silveiro, Cátia ; Marques, Mariana ; Olivença, Francisco...
2235-2988. , 2023

Link: http://hdl.handle.net/10..

7

Identification of drivers of mycobacterial resistance to pe..:

Olivença, Francisco ; Ferreira, Cláudia ; Nunes, Alexandra...
info:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FBIA-MIC%2F31233%2F2017/PT. , 2023

Link: http://hdl.handle.net/10..

8

CRISPRi-mediated characterization of novel anti-tuberculosi..:

Silveiro, Cátia ; Marques, Mariana ; Olivença, Francisco...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050696/. , 2023

Link: http://www.ncbi.nlm.nih...

9

WGS-based dual strategy for the identification of key targe..:

Olivença, Francisco ; Nunes, Alexandra ; Macedo, Rita...
http://hdl.handle.net/10400.14/42191. , 2023

Link: http://hdl.handle.net/10..

10

Uncovering Beta-Lactam Susceptibility Patterns in Clinical ..:

Olivença, Francisco ; Nunes, Alexandra ; Macedo, Rita...
info:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FBIA-MIC%2F31233%2F2017/PT. , 2023

Link: http://hdl.handle.net/10..

11

Identification of drivers of mycobacterial resistance to pe..:

Olivença, Francisco ; Ferreira, Cláudia ; Nunes, Alexandra...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485614/. , 2022

Link: http://www.ncbi.nlm.nih...

12

Uncovering Beta-Lactam Susceptibility Patterns in Clinical ..:

Olivença, Francisco ; Nunes, Alexandra ; Macedo, Rita...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431576/. , 2022

Link: http://www.ncbi.nlm.nih...

13

The Mycobacteriophage Ms6 LysB N-Terminus Displays Peptidog..:

Gigante, Adriano M ; Olivença, Francisco ; Catalão, Maria João...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309991/. , 2021

Link: http://www.ncbi.nlm.nih...

14

The mycobacteriophage ms6 lysb n-terminus displays peptidog..:

Gigante, Adriano M ; Olivença, Francisco ; Catalão, Maria João...
info:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FIMI-MIC%2F0694%2F2012/PT. , 2021

Link: http://hdl.handle.net/10..

15

CRISPRi-mediated characterization of novel anti-tuberculosi..:

Cátia Silveiro ; Mariana Marques ; Francisco Olivença...
https://www.frontiersin.org/articles/10.3389/fcimb.2023.1089911/full. , 2023

Link: https://doi.org/10.3389/..